AstraZeneca gets six more months of Arimidex exclusivity

WILMINGTON, Del. The Food and Drug Administration has granted AstraZeneca an additional six-month period of exclusivity to market Arimidex for its breast cancer indications until June 2010.

The drug is currently approved to treat postmenopausal women with hormone receptor positive early breast cancer following surgery or without radiation. The drug is also indicated for first-line treatment for unknown locally advanced or metastatic breast cancer, as well as treatment following tamoxifen therapy.

In the U.S., Arimidex sales were $507 million for the first nine months of 2007.